Skip to content
Menu

Mineralys Therapeutics, Inc. MLYS

Full chart Compare
Set alert

Price alert · MLYS

All alert types
13.62 USD -0.54 (-3.81%)

As ofNov 20, 2026, 3:44 PM EST

13.57 Day range 14.08
13.57 52-week range 44.13
YTD
-62.47%
1 year
-67.47%

5D -1.37 (-8.98%)

1414.5015MonTueWedThuFri13.89
Market cap
1.21B
EPS (ttm)
-4.30
Shares out
88.56M
Forward P/E
-5.84
YTD return
-62.47%
1-year return
-67.47%
50-day average
21.72
200-day average
25.90
Enterprise value
693.92M
Price / book
2.49
Volume
856.59K
Avg volume
1.54M
Open
14.08
Previous close
14.16
Day's range
13.57 – 14.08
52-week range
13.57 – 44.13
Beta
0.82
Analysts
Strong Buy
Price target
43.56 (+219.8%)
Earnings date
Mar 11, 2027

Key statistics

Free cash flow
-210.65M
Total cash
624.67M
Total debt
98.27M
Return on equity
-68.50%
Short % of float
10.39%

Fundamental scorecard

4 of 25 checks passed on MLYS’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MLYS Revenue — quarterly 0
MLYS Net income — quarterly -57.33M
MLYS EPS — quarterly -0.64

Earnings

MLYS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 11, 2027Mar 30, 2027-0.65———
Nov 4, 2026Sep 30, 2026-0.5548-0.64-0.09-15.36%
Aug 12, 2026Jun 30, 2026-0.54857-2.85-2.30-419.53%
May 6, 2026Mar 31, 2026-0.51-0.47+0.04+7.84%
Mar 12, 2026Dec 31, 2025-0.51625-0.40+0.12+22.52%
Nov 10, 2025Sep 30, 2025-0.66-0.52+0.14+21.21%

Upgrades / downgrades

MLYS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026UBSinit—Neutral
Oct 12, 2026HC Wainwright & Co.reitBuyBuy
Apr 27, 2026TD Coweninit—Buy
Mar 13, 2026B of A SecuritiesmainBuyBuy
Dec 19, 2025StifelmainBuyBuy
Nov 12, 2025HC Wainwright & Co.mainBuyBuy

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MLYS — it syncs with the Stock Master app.

Insider holders

MLYS insider holders
InsiderRelationLatest transactionDateShares held
AKKARAJU SRINIVASDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Feb 18, 20265,877,220
CONGLETON JONChief Executive OfficerSaleJul 12, 2026603,621
FERGUSON JAMES J. IIIOfficerStock Award(Grant)Aug 9, 2026102,400
KARYDAS DAPHNEDirectorConversion of Exercise of derivative securitySep 14, 20266,200
LEVY ADAM SCOTTChief Financial OfficerStock Award(Grant)Feb 18, 202648,538
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 29, 20260

Institution ownership

MLYS institution ownership
Holder% heldSharesValueReported
Catalys Pacific, LLC8.81%7,799,518110.44MSep 29, 2026
RA Capital Management, L.P.8.69%7,692,750108.93MSep 29, 2026
Blackrock Inc.6.97%6,172,15387.40MSep 29, 2026
Samsara BioCapital, LLC6.63%5,871,01883.13MSep 29, 2026
FMR, LLC5.32%4,713,19566.74MSep 29, 2026
Deerfield Management Company, L.P4.47%3,958,00056.05MSep 29, 2026

Fund ownership

MLYS fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc2.83%2,502,85435.44MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.22%1,968,12427.87MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.79%1,584,49322.44MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.66%1,468,68920.80MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.33%1,180,00016.71MSep 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund1.09%962,99913.64MSep 29, 2026